Heart failure (HF) is a progressive disease. It is estimated that more than 250,000 patients suffer from advanced HF with reduced ejection fraction refractory to medical therapy. With limited donor pool for heart transplant, continue flow left ventricle assist device (LVAD) is a lifesaving treatment option for patients with advanced HF. This review will provide an update on indications, contraindications, and associated adverse events for LVAD support with a summary of the current outcomes data.
Keyphrases
- heart failure
- acute heart failure
- end stage renal disease
- left ventricular assist device
- ejection fraction
- pulmonary artery
- pulmonary hypertension
- newly diagnosed
- healthcare
- chronic kidney disease
- multiple sclerosis
- atrial fibrillation
- big data
- type diabetes
- left ventricular
- patient reported outcomes
- machine learning
- congenital heart disease
- mesenchymal stem cells
- data analysis
- insulin resistance